Spineart acquires worldwide rights to βgel® bone substitute gel

Spineart announced today that it acquired a portfolio of proprietary synthetic orthobiologic solutions from Orthos Ltd including the worldwide rights to βGel® and βGran®.
βGel® is an innovative osteoconductive scaffold in the form of a versatile, pre-mixed, malleable gel with unique handling characteristics even when compared to allografts. βGel® stiffens and becomes resistant to displacement by body fluids as it reaches body temperature. Its interconnected porosity is controlled to provide a three-dimensional scaffold that supports vascularisation and early cell attachment in order to function as an osteoconductive template.
βGran® is a range of high purity synthetic osteoconductive scaffolds intended to be used as bone void fillers in the treatment of osseous defects which occur as a result of trauma or in surgically created defects. βGran® has been successfully used to treat bone loss resulting from trauma to resolve conduction defects in non-unions and to restore conduction across osteotomy sites. In spinal fusion βGran® has proved extremely effective at expanding the volume of available fusion material as it can be combined with any autograft harvested during the surgical procedure.
About Spineart :
Spineart delivers pioneering, safe and efficient solutions to spine surgeons, operating room teams and patients.
Spineart, present in 47 countries, offers a full range of high quality Swiss Made Fusion, Motion, and MIS devices worldwide, focusing on simplicity and safety of use.
Spineart markets a complete portfolio of traceable barcoded sterile packed implants and is thereby proudly promoting higher safety, cost-efficiency, and compliance at the hospital.
For more information please contact us at contact@spineart.com or visit spineart.com.